Elsevier

Vaccine

Volume 29, Issue 3, 10 January 2011, Pages 599-612
Vaccine

Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data

https://doi.org/10.1016/j.vaccine.2010.06.003Get rights and content

Section snippets

Need for developing a standardized case definition and guidelines for Guillain–Barré syndrome (GBS) and Fisher syndrome (FS) as an adverse event following immunization

Among the various events reported as adverse outcomes following immunizations, neurologic adverse events following immunization (AEFI) are among the most severe and the most difficult to assess. The multifaceted presentation of neurologic illness, the relative lack of familiarity of many clinicians with the approach to and diagnosis of neurologic disease, and the relative scarcity of trained neurologists in many parts of the world make neurologic AEFI some of the most challenging issues in

Clinical case definitions: Guillain–Barré syndrome (GBS)3,4,5

  • Level 1 of diagnostic certainty

    • Bilateral AND flaccid weakness of the limbs6,7,8

Guidelines for data collection, analysis, and presentation of GBS and FS as adverse events following immunization

It was the consensus of the Brighton GBS Working Group to recommend the following guidelines to enable meaningful and standardized collection, analysis, and presentation of information about GBS and FS23. However, the implementation of all guidelines might not be possible in all settings. The availability of information may vary depending upon resources, geographic

Acknowledgements

The authors are grateful for the support and helpful comments from members of Brighton Collaboration Steering Committee during the time of the development of this document, who are not already included as authors (Mike Blum, Paul Heath, Hector Izurieta, Brigitte Keller Stanislawski, Katrin Kohl Odile Leroy), and the participants in the Reference Group (Adam Rudiger, Adderson Elisabeth, Aguilar Maria, Aldrovandi Grace, Allen Mary, Bachtiar Novilia Sjafri, Barami A. A. Salim, Baxter Roger,

First page preview

First page preview
Click to open first page preview

References (85)

  • M. Alter

    The epidemiology of Guillain–Barre syndrome

    Ann Neurol

    (1990)
  • V. Govoni et al.

    Epidemiology of the Guillain–Barre syndrome

    Curr Opin Neurol

    (2001)
  • A. McGrogan et al.

    The epidemiology of Guillain–Barre Syndrome worldwide. A systematic literature review

    Neuroepidemiology

    (2008 Dec 17)
  • B.S. Schoenberg

    Epidemiology of Guillain–Barre syndrome

    Adv Neurol

    (1978)
  • R.A. Hughes et al.

    Clinical and epidemiologic features of Guillain–Barre syndrome

    J Infect Dis

    (1997)
  • D. Orlikowski et al.

    Respiratory dysfunction in Guillain–Barre syndrome

    Neurocrit Care

    (2004)
  • D.D. Fletcher et al.

    Long-term outcome in patients with Guillain–Barre syndrome requiring mechanical ventilation

    Neurology

    (2000)
  • D.R. Cornblath et al.

    Guillain–Barre syndrome

  • H.R. Jones

    Guillain–Barre syndrome in children

    Curr Opin Pediatr

    (1995)
  • J.T. Sladky

    Guillain–Barre syndrome in children

    J Child Neurol

    (2004)
  • N.K. Singh et al.

    Prognostic factors in Guillain–Barre’ syndrome

    J Assoc Phys India

    (1994)
  • J.H. Rees et al.

    Epidemiological study of Guillain–Barre syndrome in south east England

    J Neurol Neurosurg Psychiatry

    (1998)
  • A.K. Asbury

    New concepts of Guillain–Barre syndrome

    J Child Neurol

    (2000)
  • J.W. Griffin et al.

    Guillain–Barre syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases

    Brain

    (1995)
  • G.M. McKhann et al.

    Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China

    Ann Neurol

    (1993)
  • J.R. Overell et al.

    Recent developments in Miller Fisher syndrome and related disorders

    Curr Opin Neurol

    (2005)
  • C.L. Yuan et al.

    Miller Fisher syndrome: a hospital-based retrospective study

    Eur Neurol

    (2000)
  • R.D. Hadden et al.

    Electrophysiological classification of Guillain–Barre syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain–Barre Syndrome Trial Group

    Ann Neurol

    (1998)
  • J.W. Griffin et al.

    Pathology of the motor-sensory axonal Guillain–Barre syndrome

    Ann Neurol

    (1996)
  • K. Mizoguchi

    Anti-GQ1b IgG antibody activities related to the severity of Miller Fisher syndrome

    Neurol Res

    (1998)
  • J.H. Rees et al.

    Campylobacter jejuni infection and Guillain–Barre syndrome

    N Engl J Med

    (1995)
  • R. Schmidt-Ott et al.

    Improved serological diagnosis stresses the major role of Campylobacter jejuni in triggering Guillain–Barre syndrome

    Clin Vaccine Immunol

    (2006)
  • B.C. Jacobs et al.

    The spectrum of antecedent infections in Guillain–Barre syndrome: a case-control study

    Neurology

    (1998)
  • M. Mori et al.

    Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain–Barre syndrome

    Neurology

    (1999)
  • T. Nakamura

    Infectious agents as the triggers for the pathogenesis of the neuroimmunological disorders

    Nippon Rinsho

    (2008)
  • K. Susuki et al.

    Acute motor axonal neuropathy after Mycoplasma infection: evidence of molecular mimicry

    Neurology

    (2004)
  • C.C. Tam et al.

    Influenza, Campylobacter and Mycoplasma infections, and hospital admissions for Guillain–Barre syndrome, England

    Emerg Infect Dis

    (2006)
  • J. Wanschitz et al.

    Acute motor and sensory axonal neuropathy in Burkitt-like lymphoma

    Muscle Nerve

    (2006)
  • B.M. Koffman et al.

    Neurologic complications after surgery for obesity

    Muscle Nerve

    (2006)
  • F. Kalume et al.

    Molecular mimicry: cross-reactive antibodies from patients with immune-mediated neurologic disease inhibit neuronal firing

    J Neurosci Res

    (2004)
  • M.C. Levin et al.

    Neuronal molecular mimicry in immune-mediated neurologic disease

    Ann Neurol

    (1998)
  • Cited by (476)

    • High risk and low prevalence diseases: Guillain-Barré syndrome

      2024, American Journal of Emergency Medicine
    View all citing articles on Scopus

    The findings, opinions, conclusions, and assertions contained in this consensus document are those of the individual members of the Working Group. They do not necessarily represent the official positions of each participant's organization (e.g., government, university, or corporations). The findings and conclusions in this paper have not been formally disseminated by the U.S. Centers for Disease Control and Prevention or the U.S. Food and Drug Administration, and should not be construed to represent any Agency determination or policy.

    1

    Retired.

    2

    Homepage of the Brighton Collaboration: http://www.brightoncollaboration.org.

    View full text